Featured Courses
Severe Hypertriglyceridaemia: Defining the Disease and Its Management
- 1.00
Published:
Learning objectives
- Recall the mechanisms that make TGs a risk factor for atherosclerosis
- Review how elevated FCS is a major risk factor for pancreatitis
- Discuss the current clinical evidence of TG-lowering therapies in different disease states
Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention
- 1.00
Published:
Learning objectives
- Define residual inflammatory risk (RIR) and explain why cardiovascular events continue to occur in patients despite optimal lipid-lowering and antihypertensive therapies
- Describe the pathophysiological role of inflammation in atherosclerosis, myocardial infarction, heart failure and chronic kidney disease
- Identify patients at increased cardiovascular risk due to elevated inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP)
- Interpret the clinical significance of hsCRP and other inflammatory biomarkers in primary and secondary prevention settings, in alignment with current evidence and guideline recommendations
- Assess clinician practices, barriers and strategies for integrating inflammatory risk assessment and management
- Apply key takeaways to inform future risk assessment and treatment decisions in patients with or at risk for cardiovascular disease
Translating Aortic Stenosis Guidelines Into Practice: Evidence-Based Decisions for the Heart Team
- 1.00
Published:
Learning objectives
- Recall recent guideline recommendations for the management of aortic stenosis
- Summarise the evidence supporting TAVI across the sub-groups of aortic stenosis, age and surgical risk
- Develop an expert guided approach to patient selection and referral for TAVI
- Adopt an evidence-based approach for the lifetime management of younger patients with aortic stenosis
Revolutionising Thrombosis Treatment in ACS, SSP and AF
- 1.00
Published:
Learning objectives
- Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
- Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
- Review guidelines and critique current prescribing practices and the implications of inadequate treatment
- Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
- Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
- Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
The Rise of CVRM Medicine: Managing Common Co-morbidities as One
- 3.00
Published:
Learning objectives
- Describe the link between T2DM, CKD and ASCVD
- State the importance of early and effective intervention in managing CVRM disease progression
- List the guideline directed therapeutic targets in CVRM disease
- Select appropriate patients for holistic CVRM management
- Recall trial data for novel therapeutic agents that carry benefit for CVRM outcomes
- Develop a holistic management strategy for CVRM disease with an evidence-based impact on clinical outcomes
Managing Hypertension in CVD: How Low Can We Go?
- 1.00
Published:
Learning objectives
- Describe the link between CVD and hypertension
- Classify hypertension patients according to their cardiovascular risk
- Recall recent guideline-directed and evidence-based strategies for managing very high CVD risk patients
- Apply guideline-directed and evidence-based management strategies to a case study
- Use expert guidance to adopt optimal multidisciplinary antihypertensive management strategies in patients with very high cardiovascular risk
TAVI Index Procedure: The Value of Valve Optimisation on Long-term Outcomes and Lifetime Management
- 1.00
Published:
Learning objectives
- Recall the critical steps in lesion preparation and on post dilation to optimise valve implantation when needed
- Recognise the technical considerations in precise valve positioning and deployment for larger annuli patients
- Explore the long-term implications of index procedure optimisation on patient management and outcomes
- Engage with an expert operator through a live case demonstration and interactive discussion
Unravelling the Pathways to Early Intervention in ATTR-CM
- 1.00
Published:
Learning objectives
- Review the binding affinity for current stabilising agents
- Recall the trajectory of disease progression in ATTR-CM
- Discuss future options for individuals who progress on treatment
Available Courses
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
Advancing Patient Care in Hypertrophic Cardiomyopathy
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
Advancing Tricuspid Valve Replacement
- 1.00
Published:
Learning objectives
- List clinical trial data and real-world evidence for TTVR
- Recall guideline recommendations for TTVR
- Select appropriate patients for TTVR based on the heart-team and patient choice
- Use expert guidance to develop an evidence-based approach to managing TR with TTVR
AF Stroke Prevention – Applying New Guidance in the Real World
- 1.00
Published:
Learning objectives
- Recall the risk of ischaemic stroke in AF patients
- Compare therapeutic efficacy and risk between left atrial appendage closure and oral anticoagulation in atrial fibrillation
- Review European guideline updates on the use of left atrial appendage closure in atrial fibrillation
- Summarise the clinical evidence behind non-pharmacological approaches to stroke prevention in atrial fibrillation
An Expert Approach to Cardio-Renal Protection in CKD
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
Bridging the Gap in Worsening Heart Failure: Evidence-Based Approaches to Optimising Treatment Outcomes
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
Most Recent
Advancing Tricuspid Valve Replacement
- 1.00
Published:
Learning objectives
- List clinical trial data and real-world evidence for TTVR
- Recall guideline recommendations for TTVR
- Select appropriate patients for TTVR based on the heart-team and patient choice
- Use expert guidance to develop an evidence-based approach to managing TR with TTVR
Severe Hypertriglyceridaemia: Defining the Disease and Its Management
- 1.00
Published:
Learning objectives
- Recall the mechanisms that make TGs a risk factor for atherosclerosis
- Review how elevated FCS is a major risk factor for pancreatitis
- Discuss the current clinical evidence of TG-lowering therapies in different disease states